Author:
Jakub Svoboda ,Steven M. Bair ,Daniel J. Landsburg ,Sunita Dwivedy Nasta ,Sarah J. Nagle ,Stefan K. Barta ,Nadia Khan ,Joanne Filicko-O'Hara ,Sameh Gaballa ,Lauren Strelec ,Elise Chong ,Sheryl Mitnick ,Terease S. Waite ,Cara King ,Hatcher Ballard ,Matthew Youngman ,James Gerson ,John P. Plastaras ,Amit Maity ,Agata M. Bogusz ,Stacy S. Hung ,Hisae Nakamura ,Reza Nejati ,Christian Steidl ,Megan Lim ,Marco Ruella ,Stephen J. Schuster
Abstract
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献